CELL
CLONOGENICITY

A single cell that has the ability to rapidly clone itself and grow into a full colony

CELL
MIGRATION

Cells that have elongated and transformed their cell structure to move through the extracellular matrix

CELL
DORMANCY

Live cells that are not dividing or migrating

Exploiting the phenotypic states of cancer to identify new avenues of diagnosis and treatment

ABOUT US

SINGLECELL BIOTECHNOLOGY

Launched in February of 2022
Licensed technology from The UT Southwestern Medical Center
Located in the heart of North Texas Bio Community at Pegasus Park, Dallas

OUR TEAM

Bryan Presley - President
Digant Dave', PhD - Science Advisor
Robert Bachoo, MD, PhD - Science Advisor
Elizibeth Maher, MD, PhD - Science Advisor
Azam Anwar, MD - Chairman

About Us

Technology

TECHNOLOGY

SingleCell Biotechnology has developed a new platform of assays to target highly aggressive and invasive cancers. The platform consists of three phenotype assays that recapitulate dormancy, migration, and single cell clonogenicity of tumor stem cells. These stem cells make up the hallmark characteristics of aggressive and highly invasive cancers responsible for recurrence and mortality. Each assay is designed to collect high content and high throughput data necessary for drug discovery and disease analysis. The platform can be used for screening drug libraries and identifying druggable targets for killing or disrupting dormant and migrating cells to expedite and de-risk the drug development process.

The SingleCell Bio platform uses proprietary protocols and 3D spatial confinement of single cells in massive arrays that allow downstream cell retrieval for multi-omic profiling. By combining high-content imaging with molecular analysis, our platform can be used to construct a phenotype-to-genotype map of each individual patient's cancer that can be used in predictive technologies and disease progression.

Our platform can be used with all solid tumor cancer cells. Currently we have demonstrated use with Glioblastoma and Breast Cancer and are looking for partners to explore usage in these and other cancers.

Partnerships

PARTNERSHIPS

We are actively seeking partnerships with drug developers and research organizations focused on developing more effective drugs and treatments for cancer and cancer recurrence.

NEWS

11/15/2023

SingleCell Biotechnology awarded CPRIT Grant to optimize and advance its assays for use in drug development against Glioblastoma (GBM) brain tumors.

Award

08/20/2023

SingleCell Biotechnology successfully tests platform with primary patient agnostic GBM samples.

01/25/2023

SingleCell Biotechnology successfully tests platform devices with GBM and Breast Cancer patient derived cell lines.

News

CONTACT US

Our Address

3060 Pegasus Park Dr., Dallas, TX 75247

The Biotech Hub of Dallas

Pegasus Park - Biotech Hub

CELL CLONOGENICITY